Equities

Neuland Laboratories Ltd

NEULANDLAB:NSI

Neuland Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)12,712.65
  • Today's Change72.90 / 0.58%
  • Shares traded7.70k
  • 1 Year change+245.92%
  • Beta1.3663
Data delayed at least 15 minutes, as of Sep 20 2024 09:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,167590236
Total Receivables, Net4,2693,9672,689
Total Inventory3,6622,9452,802
Prepaid expenses11110574
Other current assets, total2.551.166.83
Total current assets9,2117,6095,808
Property, plant & equipment, net5,6864,9804,866
Goodwill, net2,7952,7952,795
Intangibles, net251321
Long term investments203199202
Note receivable - long term32012585
Other long term assets857759
Total assets18,32615,79813,835
LIABILITIES
Accounts payable1,9201,7101,174
Accrued expenses1,011591415
Notes payable/short-term debt0112922
Current portion long-term debt/capital leases413392371
Other current liabilities, total9341,585749
Total current liabilities4,2774,3903,632
Total long term debt5417811,112
Total debt9541,2842,405
Deferred income tax604583567
Minority interest------
Other liabilities, total76103119
Total liabilities5,4995,8575,430
SHAREHOLDERS EQUITY
Common stock129129129
Additional paid-in capital4,9784,9784,978
Retained earnings (accumulated deficit)7,8044,9323,361
Treasury stock - common------
Unrealized gain (loss)(53)(61)(27)
Other equity, total(31)(36)(35)
Total equity12,8279,9418,405
Total liabilities & shareholders' equity18,32615,79813,835
Total common shares outstanding131313
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.